Background: In patients with heavy proteinuria, corticosteroid therapy has been shown to have favorable effects on the progression of IgA nephropathy. However, the efficacy of corticosteroids on the progression of IgA nephropathy with moderate proteinuria is still controversial.
Methods: We assessed 45 adult (age, 18-50 years) patients with moderate proteinuria (0.5-2.0 g daily) and preserved renal function, (serum creatinine concentration, < or = 106 micromol/l) who were diagnosed as having primary IgA nephropathy between December 1993 and July 1998. Twenty-three of the patients were treated with corticosteroids (steroid group), and the remaining 22 patients had no steroid treatment (control group). All patients were followed up for more than 3 years.
Results: There were no differences in baseline characteristics between the two groups, except for proteinuria. In the steroid group, urinary protein excretion was significantly higher than that in the control group. During the follow-up period, urinary protein excretion was not changed in the control group. On the other hand, in the steroid group, mean urinary protein excretion decreased significantly. Seven patients in the control group and 2 patients in the steroid group reached the endpoint, which was defined as a 50% increase in serum creatinine concentration from baseline. Renal survival curves were significantly different between the two groups. A second biopsy was performed in 20 patients who received steroid therapy. Mesangial cell proliferation, mesangial matrix increase, and cellular crescents were significantly reduced in the second compared with the first biopsy specimens.
Conclusions: Steroid therapy is effective in reducing the progression of IgA nephropathy with moderate proteinuria.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10157-003-0236-0 | DOI Listing |
Gut Microbes
December 2025
State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
IgA nephropathy (IgAN) is related to the balance of gut microbiota. However, it is unclear whether changes in the gut microbiota can cause IgAN or attenuate its progression. This study employed IgAN and human microbiota-associated (HMA)-IgAN models to investigate the impact of IgAN on gut microbiota alteration and the mechanisms by which gut microbiota might trigger IgAN.
View Article and Find Full Text PDFClin Kidney J
January 2025
Department of General Internal Medicine and Nephrology, Robert Bosch Hospital Stuttgart, Stuttgart, Germany.
Background: Sparsentan, a dual-acting antagonist for both the angiotensin II receptor type 1 and the endothelin receptor type A, has emerged as a promising therapeutic agent for the treatment of IgA nephropathy (IgAN). Following the publication of the PROTECT trial, sparsentan recently received approval for the treatment of IgAN in Europe. However, it remains uncertain whether an additive effect can be observed in the context of existing treatment with sodium-glucose co-transporter 2 (SGLT2) inhibitors, given that the PROTECT study did not investigate this dual therapy approach.
View Article and Find Full Text PDFIndian J Nephrol
October 2024
UOC Nefrologia Dialisi e Trapianto, IRCCS Istituto Giannina Gaslini, Largo Gerolamo Gaslini, Genova, Italy.
Indian J Nephrol
August 2023
Department of Nephrology, Zydus Hospital, Ahmedabad, Gujarat, India.
Fibrillary and immunotactoid glomerulonephritis represent the pathological entities characterized by structured fibrillary/microtubular deposits, whose identification is possible only by electron microscopy. We report a 46-year-old female who presented with proteinuria 15 years after the onset of psoriasis. Diffuse global glomerulosclerosis pattern was noted on light microscopy.
View Article and Find Full Text PDFMed J Armed Forces India
July 2023
Resident (Nephrology), Army Hospital (R&R), Delhi Cantt, India.
Sarcoidosis is a multisystem granulomatous disease of unknown etiology, characterized by noncaseating epithelioid granuloma, multinucleate giant cells, and tissue destruction. While lung and lymph node involvement is common, isolated renal involvement is rare. We report the case of a 55-year-old female patient, with renal limited sarcoidosis, who presented with worsening sensorium and acute kidney injury.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!